In addition, there were no differences in daytime activity indices or in sleep parameters between the evening and morning initial treatment schedules
Yet, the efficiency of such interventions is, in many cases, limited, and additional, second-line treatments are frequently implemented, that mainly involve the use of metformin, as insulin-sensitizer, with variable efficacy in terms of improvement of reproductive and metabolic alterations
Clinical trials show non-diabetic patients lose 10 to 22 percent of baseline body weight over 68 weeks, depending on dose and adherence
For a member who is successful in utilizing a GLP-1, the co-therapy requirement is for 24 months
Note that some people with more insulin resistance will not lose weight until they're on the slightly higher dose in the second or third month